Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $28.3344.

BCAX has been the subject of several research reports. Wedbush reissued an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, January 13th. Wells Fargo & Company increased their price target on Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Citizens Jmp assumed coverage on shares of Bicara Therapeutics in a research report on Thursday. They set a “market perform” rating and a $31.00 target price for the company. Finally, Citigroup began coverage on shares of Bicara Therapeutics in a research note on Thursday. They issued an “outperform” rating for the company.

Insider Buying and Selling at Bicara Therapeutics

In other news, COO Ryan Cohlhepp sold 3,828 shares of Bicara Therapeutics stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $18.10, for a total value of $69,286.80. Following the completion of the transaction, the chief operating officer directly owned 210,164 shares in the company, valued at approximately $3,803,968.40. The trade was a 1.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Raben sold 5,500 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $18.45, for a total value of $101,475.00. Following the sale, the insider directly owned 35,497 shares in the company, valued at $654,919.65. This trade represents a 13.42% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 95,922 shares of company stock worth $1,784,142. 15.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vestal Point Capital LP lifted its holdings in shares of Bicara Therapeutics by 80.6% in the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after buying an additional 2,231,025 shares in the last quarter. Bank of America Corp DE lifted its stake in Bicara Therapeutics by 2,351.0% in the 2nd quarter. Bank of America Corp DE now owns 451,228 shares of the company’s stock worth $4,192,000 after purchasing an additional 432,818 shares in the last quarter. Artisan Partners Limited Partnership bought a new position in Bicara Therapeutics in the 2nd quarter valued at $3,742,000. Schroder Investment Management Group grew its position in shares of Bicara Therapeutics by 921.0% during the 2nd quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock valued at $3,951,000 after purchasing an additional 383,681 shares in the last quarter. Finally, Nan Fung Trinity HK Ltd. purchased a new position in shares of Bicara Therapeutics during the 2nd quarter valued at $3,185,000.

Bicara Therapeutics Stock Performance

NASDAQ BCAX opened at $16.91 on Friday. The company has a market capitalization of $926.33 million, a PE ratio of -7.55 and a beta of -0.79. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $19.71. The company has a 50-day simple moving average of $17.54 and a 200 day simple moving average of $14.84.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). As a group, analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.